Wachtell Lipton Guiding AbbVie On $10.1B ImmunoGen Buy
AbbVie Inc. said Thursday it has agreed to buy cancer drugmaker ImmunoGen Inc. at a total equity value of approximately $10.1 billion, with representation from Wachtell Lipton Rosen & Katz, sending the...To view the full article, register now.
Already a subscriber? Click here to view full article